CytoCore Announces 2nd Quarter Financial Results.

New CEO, President and Marketing Director for e2 Collector Rollout

CHICAGO -- CytoCore (OTCBB:CYCR), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced financial results for the second quarter 2007.

CytoCore substantially improved liquidity since its Q2 2006 results. The company reduced operating losses 68%, from $3.17 million in June 2006 to $1.01 million in June 2007. CytoCore raised $5.37 million through the issuance of common stock and conversion of warrants during the first six months of 2007 as the company ramped up clinical trials and product development. CytoCore's cash balance position improved 300%, from $874,000 in June 2006 to $2.63 million at the close of June 2007. In addition, CytoCore further strengthened its balance sheet by reducing debt 61% from $6.922 million in June of 2006 to $2.67 million at the end of the second quarter.

"CytoCore has significantly reduced liabilities from approximately $14 million in August 2005," said Robert McCullough Jr., Chief Financial Officer. "We continue to reduce the balance, and believe we can achieve our goal of reducing liabilities to approximately $500,000 by year's end while we focus our resources on product development and clinical trials prior to our launch of the cervical cell collector later this year. We expect a large portion of this reduction in liabilities will occur without the use of cash."

Besides having a solid financial quarter, CytoCore significantly strengthened its scientific and management teams. Dr. Floyd Taub joined the company as CEO. Dr. Taub's past success as developer of the HPV test and founder of Digene demonstrate a proven ability in developing and taking product from concept to the commercial stage. As a recognized leader in women's reproductive health care, his experience enables CytoCore to expand its capabilities and explore further opportunities in the field of women's health care. Additionally this quarter, Dick Domanik was appointed President. His experience and capabilities are ideally matched with CytoCore's strategic direction. His successful product development history should substantially improve and expedite the development of CytoCore's products and their sales performance over time.

In addition, CytoCore has appointed Dan McMahon as Director of Marketing, to lead product marketing efforts for the upcoming launch of the e2 Collector. McMahon's extensive strategic and tactical marketing experience with global leaders such as Baxter International and VIASYS Healthcare round out CytoCore's management team. McMahon's product development and launch experience includes the successful introductions of nine new technologies in medical devices and therapeutics that improved the standard of care and reshaped the health care landscape. In conjunction with the near-term approval of the CE mark, former CEO Dr. Augusto Ocana, who has strong distribution connections into Europe, is aggressively developing distribution agreements for the e2 Collector in a number of European countries.

On the science front, Dr. George Gorodeski had a second major paper published on the P2X7 marker and presented at two notable scientific conferences in the second quarter. He presented new findings showing that the P2X7 is capable of identifying pre-cancerous tissues, and that it could be modified to potentially be used in therapies to halt the advance or reverse the spread of cancer in certain tissue types. Such capabilities represent a significant breakthrough for the P2X7 gene and for future CytoCore products.

"With the strong progress we've made across the board this past quarter, CytoCore is in much better position to successfully begin the e2 Collector's sales and expand product development activities," said CFO McCullough. "We will shift into new product sales this fall, and expect solid results once again as we continue to grow the company."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening, therapeutic and delivery systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.